DOD Deployment Related Medical Research Program

The summary for the DOD Deployment Related Medical Research Program grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DOD Deployment Related Medical Research Program: The DRMRP Advanced Technology/Therapeutic Development Award mechanism is being offered for the first time in FY08. The intent of this award is to provide support for the assessment of scientific and/or military field deployment feasibility for promising new products, pharmacologic agents (drugs or biologics), behavioral interventions, devices, clinical guidance, and/or emerging approaches and technologies. These awards are expected to yield potential deployment-related health products, approaches, or technologies positioned for human testing. The products to be developed may be pharmacologic agents (drugs, biologicals), cognitive/behavioral intervention, devices, or clinical guidance. Military relevance is a key feature of this award. Therefore, PIs are strongly encouraged to collaborate and integrate their projects with military and/or Veterans Affairs (VA) research laboratories and programs. Each PI must provide a transition plan (including funding and resources) showing how the product will progress to clinical trials and/or delivery to the military market after the successful completion of this DRMRP award. All proposals must be responsive to the healthcare needs of deployed members of the Armed Forces. Examples of the types of research that may be supported include, but are not limited to: . Collection and analysis of data for developing and validating clinical guidance. . Developing new behavioral interventions. . Testing new therapeutic modalities (agents, delivery systems, chemical modification of lead compounds) using established or validated novel preclinical systems. . Comparative activity/efficacy testing to define a single lead agent from a limited library of candidates. . Designing and implementing full-scale, pilot Good Manufacturing Practice (GMP) production of therapeutics and/or delivery systems for use in advanced preclinical and initial clinical trials. . Developing pharmacologic agents through the elements of absorption, distribution, metabolism, excretion, and toxicity (ADMET). . Developing pharmacologic agents to Investigational New Drug (IND) stage for initiation of Phase I clinical trials. . Developing prototype devices for diagnosis or treatment to Investigational Device Exemption (IDE) stage for initiation of Phase I clinical trials. . Development and validation of assays and reagents required to measure biological responses and molecular endpoints. . Developing and validating computational models. . Optimizing diagnostic or treatment devices for field deployment. See the Program Announcement for the full Funding Opportunity Description.